Record Details

In vitro evaluations of antimicrobial, cytotoxicity, DNA binding, cholinesterase studies of copper complexes with phenyl-selanyl ligands

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title In vitro evaluations of antimicrobial, cytotoxicity, DNA binding, cholinesterase studies of copper complexes with phenyl-selanyl ligands
 
Creator Moohambihai, P
Nagashri, K
 
Subject Antimicrobial
Cytotoxicity
DNA binding
α–glucosidase
Phenylselanyl-quinoline
 
Description 367-379
Copper (II) complexes (3a-i) with (16E)-N-(2-phenylquinolin-4(1H)-ylidine)-2-(phenylselanyl)pyridine-3-amine ligands
have been synthesized. They have been characterised by various spectroscopic studies. In-vitro cytotoxic potential has been
determined, with significant cytotoxicity against MCF-7 cell line. The copper complexes interact with the calf thymus,
(CT-DNA), according to absorption spectra and viscosity measurements. In addition, the copper complexes have been tested
for their antimicrobial activity against three Gram-negative bacteria; Proteus vulgaris, Klebsiella pneumoniae, and Shigella
flexneri, three Gram-positive bacteria; Staphylococcus aureus, Staphylococcus epidermidis, and Bacillus subtilis, and three
fungi; Aspergillus fumigatus, Aspergillus clavatus and Candida albicans. The ligand's acetylcholinesterase (AChE)
inhibiting function has been investigated in order to determine the ligand's efficacy in the treatment of neurodegenerative
disorders. When compared to standard Rivastigmine and Galantamine, the synthesised ligand 2c show selective inhibition
(AChE and BuChE) with IC50 values of 0.19 and 3.03 μM. The egg albumin method is used to test the anti-inflammatory
efficiency and α-glucosidase inhibitory activities of copper chelates are tested.
 
Date 2022-07-26T10:45:48Z
2022-07-26T10:45:48Z
2022-07
 
Type Article
 
Identifier 0975-0991 (Online); 0971-457X (Print)
http://nopr.niscpr.res.in/handle/123456789/60154
 
Language en
 
Publisher NIScPR-CSIR, India
 
Source IJCT Vol.29(4) [July 2022]